ClinicalTrials.gg
TerminatedNCT00630799Updated Sep 9, 2010

Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients

A Phase 3 interventional study of leuprolide acetate in Prostate Cancer, sponsored by GP-Pharm. Terminated at 8 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-09-09.

Sponsored by GP-Pharm · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.

Enrollment
60th of 69
20 · median 77
Started
2008
with 2 others
Phase 3
26 of 70
3 open now
Registered
17th of 70
by date
Lead sponsor
3 of 70
GP-Pharm

Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is the 60th largest by enrollment of the 69 interventional ones that give a count, is one of 3 that started in 2008, is one of 26 in phase 3, and was the 17th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing leuprolide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a multi-center, open-label study of 2 doses of leuprolide acetate 17 mg depot, administered three months apart, in subjects with prostate cancer who might benefit from medical androgen deprivation therapy

03

Conditions studied

  • Prostate Cancer

Keywords

  • prostate
  • cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males 18 years of age, with proven carcinoma of prostate, who might benefit from medical androgen deprivation therapy;
  • of at least 1 year;
  • performance status of 0, 1, or 2;
  • adequate renal function at screening as defined by serum creatinine \<= 1.6 times the (ULN) for the clinical laboratory;
  • adequate and stable hepatic function as defined by \<= 1.5 times the ULN and transaminases (i.e. , SGPT) \<= 2.5 times the ULN for the clinical laboratory at screening;
  • ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the Investigator and to comply with the requirements of the entire study;
  • signed written prior to inclusion in the study.

Exclusion criteria

Exclusion Criteria:

  • Evidence of , in the opinion of the Investigator, taking into account medical history, clinical observations and symptoms;
  • evidence of spinal cord compression, in the opinion of the Investigator, taking into account medical history, clinical observations and symptoms;
  • evidence of severe urinary tract obstruction with threatening urinary retention, in the opinion of the Investigator, taking into account medical history, clinical observations and symptoms;
  • presence of any tumor in the immediate vicinity which could cause cord compression, in the opinion of the Investigator, taking into account medical history and clinical observations;
  • excruciating, severe pain from extensive osseous deposits, in the opinion of the Investigator, taking into account medical history, clinical observations and symptoms;
  • testosterone levels \<= 1.5 ng/mL at screening, locally determined at the laboratory of each clinical site;
  • previous cancer systemic therapy such as chemotherapy, immunotherapy (e.g. antibody therapies, tumor-vaccines), biological response modifiers (e.g. cytokines) within 3 months of baseline;
  • previous hormonal therapy for treatment of prostate cancer, such as LHRH analogues (e.g. Lupron®, Zoladex®, etc.) (no wash-out allowed);
  • previous treatment with AR-receptor blockers, such as Casodex®, Fugerel®, Megace®, Androcur®(no wash-out allowed);
  • previous orchiectomy, adrenalectomy or hypophysectomy;
  • previous prostatic surgery (e.g. radical prostatectomy, transurethral resection of the prostate (TUR-P) within 2 weeks prior to or after baseline;
  • previous local therapy to the primary tumor with a curative attempt other than surgery (external beam radiotherapy, brachytherapy, thermotherapy, cryotherapy) within 2 weeks prior to or after baseline;
  • any drug within 5 half-lives of its physiological action or 3 months, whichever is longer, before baseline;
  • administration of 5-α-reductase inhibitors (Proscar®, Avodart®, Propecia®) within 3 months before baseline;
  • over-the-counter (OTC) or alternative medical therapies which have an estrogenic or anti-androgenic effect (i.e., PC-SPES, saw palmetto, Glycyrrhiza®, Urinozinc®, DHEA) within the 3 months before baseline;
  • hematological parameters (RBC, total and differential WBC count, count, , hematocrit) outside 20% of the upper or lower limits of normal (, LLN) for the clinical laboratory at screening;
  • co-existent , according to the Investigator's opinion;
  • uncontrolled congestive heart failure, myocardial infarction or a coronary vascular procedure (e.g. balloon angioplasty, coronary artery bypass graft) or significant symptomatic cardiovascular disease(s) within 6 months before baseline; resting uncontrolled hypertension: >=160/100 mmHg) or symptomatic hypotension within 3 months before baseline;
  • venous thrombosis within 6 months of baseline;
  • uncontrolled diabetes (patients with uncontrolled diabetes need to compensate the metabolic disorder before treatment with LH-RH analogues);
  • history of drug and/or alcohol abuse within 6 months of baseline;
  • serious concomitant illness(es) or disease(s) (e.g., hematological, renal, hepatic, respiratory, endocrine, psychiatric) that may interfere with, or put patients at additional risk for, their ability to receive the treatment outlined in the protocol;
  • patients on anticoagulative therapy including warfarin (Coumadin®) and heparin. Those patients on low dose low molecular weight heparin may be enrolled in the study;
  • Abnormal coagulation studies (PT/) at baseline.
  • blood donations/losses within 2 months of baseline, apart from previous prostatic surgery patients (see exclusion 10);
  • known to GnRH, GnRH agonist, including any LHRH analogues, or any of the study formulation;
  • history of the following prior to the study:

    • immunization (within 4 weeks of baseline);
    • flu shots (within 1 week of baseline or 1 week prior to and after study drug administration);
    • anaphylaxis;
    • skin disease which would interfere with injection site evaluation;
    • dermatographism will be documented at screening and followed up while on treatment.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    1

    leuprolide acetate administered by i.m. injection as two doses of 17 mg each during a period of 6 months (one dose every 3 months)

    Drug: leuprolide acetate

Interventions

06

What researchers measure

Primary outcomes

  1. Percent of successful patients achieving chemical castration

    Time frame: Days 28, 84, and 168

Secondary outcomes

  1. WHO/ECOG performance status

    Time frame: Days 14, 28, 56, 84, 112, and 168

  2. Serum LH concentration (mIU/mL)

    Time frame: Days 2, 14, 28, 56, 84, 86, 112, and 168

  3. Serum FSH concentration (mIU/mL)

    Time frame: Days 2, 14, 28, 56, 84, 86, 112, and 168

  4. Serum PSA concentration (ng/mL)

    Time frame: Days 2, 14, 28, 56, 84, 86, 112, and 168

  5. Frequency of bone pain

    Time frame: Days 2, 14, 28, 56, 54, 84, 86, 112, and 168

  6. plasma testosterone concentration (ng/mL) in PK population

    Time frame: week 4 and week 12

  7. Occurrence of hot flushes

    Time frame: Days 0, 2, 14, 28, 56, 84, 86, 112, and 168

  8. Plasma leuprolide concentrations (pg/mL) in PK population

    Time frame: Days 2, 14, 28, 56, 84, 86, 112, and 168

  9. Frequency of urinary symptoms

    Time frame: Days 2, 14, 28, 56, 54, 84, 86, 112, and 168

  10. Frequency of urinary pain

    Time frame: Days 2, 14, 28, 56, 54, 84, 86, 112, and 168

07

Study locations

8 sites
  • Advanced Research Institute
    New Port Richey, Florida 34655, United States
  • Lawrenceville Urology
    Lawrenceville, New Jersey 08648, United States
  • Hudson Valley Urology
    Poughkeepsie, New York 12601, United States
  • Piedmont Medical Research
    Winston-Salem, North Carolina 27103, United States
  • Center for Urologic Care
    Bryn Mawr, Pennsylvania 19010, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Urology Associates
    Nashville, Tennessee 37209, United States
  • Urology San Antonio Research, PA
    San Antonio, Texas 78229, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Apr 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2008
First posted
Mar 7, 2008
Start
May 2008
Primary completionActual
Apr 2009
CompletionActual
Jul 2009
Results delay requested
Aug 30, 2010
Last update
Sep 9, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00630799
Lead sponsor
GP-Pharm
First posted
Mar 7, 2008
Start date
May 2008
Primary completion
Apr 2009
Completion
Jul 2009
Last update
Sep 9, 2010

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion